small molecule

NAFTIN

NAFTIFINE HYDROCHLORIDE

Loss of exclusivityJanuary 2033latest FDA-listed patent expiry
CompanyLEGACY PHARMA INC

Drug detail

Brand nameNAFTIN
Active ingredientNAFTIFINE HYDROCHLORIDE
Strength2%
Dosage formGEL
RouteTOPICAL
ModalitySmall molecule
FDA approvalJune 2013
Marketing statusRX

Listed patents

PatentExpiresType
9161914January 2033use U-540
10729667January 2033product
8778365January 2033product
10695303January 2033product
10166206January 2033product
10166205January 2033product

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

NAFTIN patent cliff — loss of exclusivity January 2033 | CliffBio